A5087541775- Chronic Lymphocytic Leukemia Research
- Platelet Disorders and Treatments
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Autoimmune Bullous Skin Diseases
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Blood groups and transfusion
- Global Cancer Incidence and Screening
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Blood properties and coagulation
Aga Khan University Nairobi
2021-2025
University of Alabama at Birmingham
2015-2024
Aga Khan University Hospital Nairobi
2022-2024
Moi University
2022
Weatherford College
2022
Aswan University
2021
Georgia Cancer Specialists
2009-2020
O'Neal Comprehensive Cancer Center
2020
University of Alabama
2001-2019
Aga Khan University
2018
In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted 3 study the efficacy and safety combination versus gemcitabine monotherapy metastatic cancer.We randomly assigned Karnofsky performance-status score 70 or more (on scale from 0 to 100, higher scores indicating better performance status) nab-paclitaxel (125 mg per square meter body-surface area) followed by (1000...
Biosynthesis of extragonadal androgen may contribute to the progression castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor biosynthesis, prolongs overall survival among patients with metastatic cancer who have received chemotherapy.We randomly assigned, in a 2:1 ratio, 1195 had previously docetaxel receive 5 mg prednisone twice daily either 1000 acetate (797 patients) or placebo (398 patients). The primary end point was survival. secondary points...
PURPOSE: To determine the safety and efficacy of combination chimeric anti-CD20 antibody, Rituxan (Rituximab, IDEC-C2B8; IDEC Pharmaceuticals Corporation, San Diego, CA), cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy. PATIENTS AND METHODS: Forty patients with low-grade or follicular B-cell non–Hodgkin's lymphoma received six infusions (375 mg/m 2 per dose) in doses CHOP RESULTS: The overall response rate was 95% (38 40 patients). Twenty-two experienced a complete...
The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destruction and reduced production. Stimulation production may be an effective treatment for this disorder.We conducted a trial in which 118 adults with ITP counts less than 30,000 per cubic millimeter who had relapses or whose count was refractory to at least one standard were randomly assigned receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, 75 mg daily) placebo....
PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin’s lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen rituximab and has demonstrated efficacy rituximab-naïve NHL. This study evaluated ibritumomab treatment of rituximab-refractory follicular PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined no objective response (375 mg/m 2 weekly 4 weeks) time progression (TTP) ≤ 6 months. The...
PURPOSE: To evaluate the efficacy and safety of tositumomab iodine I 131 (Bexxar; Corixa Corp, Seattle, WA, GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed non-Hodgkin’s lymphoma (NHL) to compare its patients’ last qualifying chemotherapy (LQC) regimens. PATIENTS AND METHODS: Sixty who had been treated at least two protocol-specified regimens not responded progressed within 6 months after their LQC were a single course tositumomab....
PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of a chimeric anti–epidermal growth factor receptor monoclonal antibody, cetuximab, in combination with radiation therapy (RT) patients advanced squamous cell carcinoma head neck. PATIENTS AND METHODS: We treated 16 five successive treatment schedules. A standard dose escalation procedure was used; three entered onto study at each level cetuximab received conventional RT (70 Gy, 2 Gy/d), final hyperfractionated (76.8 1.2 Gy...
Purpose To compare the safety and activity of DN-101, a new high-dose oral formulation calcitriol designed for cancer therapy, docetaxel with placebo docetaxel. Patients Methods progressive metastatic androgen-independent prostate adequate organ function received weekly 36 mg/m 2 intravenously 3 weeks 4-week cycle combined either 45 μg DN-101 or taken orally 1 day before The primary end point was prostate-specific antigen (PSA) response within 6 months enrollment, defined as 50% reduction...
Purpose There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), no standard care. A randomized phase II trial showed significant gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine carboplatin (GC) in clinical rate, response progression-free (PFS), overall (OS). Here, we formally compare the efficacy these regimens III trial. Patients Methods stage IV/locally recurrent TNBC who had received more than two previous...
The phase I/II FIGHT-101 study (NCT02393248) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of pemigatinib, a potent selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, as monotherapy or in combination therapy, for refractory advanced malignancies, with without (FGF) gene alterations.Eligible, molecularly unselected patients malignancies were included part 1 (dose escalation; 3 + design) to determine the maximum tolerated dose. Part 2 expansion)...
We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and MDMX to induce cell-cycle arrest or apoptosis in TP53-wild-type (WT) tumors.Two schedules were evaluated safety, pharmacokinetics, pharmacodynamics, antitumor effects patients with solid tumors lymphomas. In arm A, received ALRN-6924 intravenous infusion once-weekly 3 weeks every 28 days; B was twice-weekly 21...
PURPOSE: This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with chemotherapy-relapsed/refractory low-grade or transformed non-Hodgkin’s lymphoma (NHL). PATIENTS AND METHODS: Patients received a dosimetric dose that consisted 450 mg anti-B1 antibody followed by 35 (5 mCi) tositumomab. Serial total-body gamma counts were then obtained to calculate patient-specific millicurie activity required deliver therapeutic...
In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an extension study this trial obtain additional safety information provide following progression.A total 247 patients documented progression received weekly intravenous study. Concurrent therapies were administered at discretion treating physician. Patient groups...
PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The directed against the Lewis-Y antigen, which expressed on 75% of all breast cancers but limited in expression normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen estimate activity BR96-doxorubicin conjugate metastatic cancer study population...
Sequence analysis of the NADPH domain (residues 158 – 293) and interface (365 478) was based on 12 CNBr fragments, which were isolated using ion‐exchange chromatography paper methods. Fragments with more than 15 residues digested further trypsin chymotrypsin. The peptides sequenced by automated solid‐phase Edman degradation. All ordered overlapped computerized comparisons a complete sequence guessed from electron density map protein. In case short this alignment confirmed protein fragments...
The angiogenic response of a progressing malignancy is characterized by shift in the balance stimulatory and inhibiting factors angiogenesis. Recognition regulated steps tumor angiogenesis provides unique targets for developing anti-tumor therapy. Vitaxin humanized monoclonal antibody, which has specificity integrin alpha v beta 3 (vitronectin receptor). This antibody can impair vascular endothelial cell growth vitro inhibit mediated pre-clinical animal models. Patients with metastatic...
Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin gpNMB-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. This phase II study investigated activity of glembatumumab advanced breast cancer by gpNMB expression.Patients (n = 124) with refractory that expressed ≥ 5% epithelial or stromal cells central immunohistochemistry were stratified expression (tumor, low intensity, high intensity)...
Purpose Anthracyclines, taxanes, and alkylating agents are among the most active in treatment of adjuvant breast cancer (BC), but optimal schedule for their administration is unknown. We performed an trial to compare sequential regimen doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) combination TAC. Patients Methods Women node-positive, human epidermal growth factor receptor 2–nonamplified, operable BC were stratified number axillary nodes hormone status randomly...
Background: TRA-8 is a murine agonist monoclonal antibody to death receptor 5 (DR5), which able trigger apoptosis in DR5 positive human tumor cells without the aid of crosslinking. It has demonstrated cytotoxicity vitro and vivo antitumor efficacy wide range solid tumors xenograft models. Tigatuzumab humanized IgG1 derived from TRA-8. Methods: A phase I trial tigatuzumab patients with relapsed/refractory carcinomas (n = 16) or lymphoma 1) was designed determine maximal tolerated dose (MTD),...